pa href="https://news.yahoo.com/reuters-health-news-summary-205720048.html"img src="" width="130" height="86" alt="Reuters Health News Summary" align="left" title="Reuters Health News Summary" border="0" /aFollowing is a summary of current health news briefs. The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events. The FDA's decision will allow the drug, developed along with Sanofi SA, to be prescribed to reduce the overall risk of major adverse cardiovascular events (MACE).pbr clear="all"
